ALOX5AP基因多态性与系统性硬化症相关间质性肺病风险相关:EUSTAR多中心研究
该研究在欧洲EUSTAR多中心队列977例SSc患者和558例健康对照中检测ALOX5AP的7个SNP,发现rs10507391多态性与SSc风险、SSc相关间质性肺病及限制性通气缺陷相关,且携带A等位基因的患者PBMC产生更多半胱氨酰白三烯。
要点
- ALOX5AP rs10507391多态性与SSc易感性相关(OR 1.27)。
- rs10507391与SSc相关间质性肺病风险相关(OR 1.45)。
- rs10507391与限制性通气缺陷(FVC<70%预计值)相关(OR 1.51)。
核心结论
- ALOX5AP遗传变异可能在SSc相关肺纤维化发生中发挥作用。
研究设计与样本
- 多中心病例对照研究,纳入EUSTAR协作中心977例SSc患者和558例健康对照,检测ALOX5AP的7个SNP。
- 对22例SSc患者,用酶免疫测定法检测离子霉素刺激的外周血单个核细胞上清中半胱氨酰白三烯和LTB4浓度。
主要发现
- rs10507391(T/A)与SSc风险相关,OR 1.27(95%CI 1.07, 1.50),P<0.05 vs 对照。
- rs10507391与高分辨率CT上SSc相关间质性肺病相关,OR 1.45(95%CI 1.17, 1.79),P<0.05 vs 无SSc相关间质性肺病患者。
- rs10507391与限制性通气缺陷(FVC<70%预计值)相关,OR 1.51(95%CI 1.16, 1.97),P<0.05 vs 无肺限制的SSc患者。
- 携带rs10507391 A等位基因的SSc患者PBMC合成的半胱氨酰白三烯多于rs10507391 TT基因型患者(P<0.05)。
- 两组间LTB4合成无显著差异。
关键数值与推荐
- rs10507391与SSc风险:OR 1.27(95%CI 1.07, 1.50),P<0.05 vs 对照。
- rs10507391与SSc相关间质性肺病:OR 1.45(95%CI 1.17, 1.79),P<0.05 vs 无SSc相关间质性肺病患者。
- rs10507391与限制性通气缺陷(FVC<70%预计值):OR 1.51(95%CI 1.16, 1.97),P<0.05 vs 无肺限制的SSc患者。
临床怎么用
- ALOX5AP rs10507391基因型可能有助于识别SSc相关间质性肺病风险较高的患者。
局限性
- 仅22例SSc患者进行了白三烯浓度检测,样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The arachidonate 5-lipoxygenase activating protein (ALOX5AP) regulates synthesis of leukotrienes (LTs), which are important mediators of inflammation and connective tissue remodelling. The aim of this study was to evaluate if single nucleotide polymorphisms (SNPs) of ALOX5AP confer risk of SSc and/or SSc-related organ involvement. METHODS: Seven SNPs of ALOX5AP (rs17222814, rs17216473, rs10507391, rs4769874, rs9551963, rs9315050 and rs7222842) were genotyped in a cohort of 977 patients with SSc and 558 healthy controls from centres collaborating within the European Scleroderma Trials and Research group. In 22 SSc patients, concentrations of cysteinyl LTs and LT B4 (LTB4) were measured in the supernatants of ionophore-stimulated peripheral blood mononuclear cells (PBMCs) by means of commercially available enzyme immunoassay kits. RESULTS: Significant association was found between rs10507391 polymorphism (T/A) of ALOX5AP and the risk of SSc [odds ratio (OR) 1.27 (95% CI 1.07, 1.50), P < 0.05 vs controls], the presence of SSc-related interstitial lung disease on high-resolution CT of the lungs [OR 1.45 (95% CI 1.17, 1.79), P < 0.05 vs patients without SSc-related interstitial lung disease] as well as with restrictive ventilatory defect [forced vital capacity <70% of predicted; OR 1.51 (95% CI 1.16, 1.97), P < 0.05 vs SSc patients without pulmonary restriction]. PBMCs from SSc carriers of rs10507391 allele A synthesized greater amounts of cysteinyl LTs as compared with SSc patients with rs10507391 TT genotype ( P < 0.05). Synthesis of LTB4 did not differ significantly between the two groups. CONCLUSION: The results of our study indicate that the genetic variants of ALOX5AP might play a role in the development of SSc-related pulmonary fibrosis.
引用
- Kowal-Bielecka O, Chwiesko-Minarowska S, Bernatowicz PL, et al. The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study. Rheumatology (Oxford). 2017. PMID: 28160477. doi:10.1093/rheumatology/kew499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。